{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:49:07Z","timestamp":1792021747293,"version":"4.4.0"},"reference-count":88,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,4,11]],"date-time":"2003-04-11T00:00:00Z","timestamp":1050019200000},"content-version":"vor","delay-in-days":69,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:p>The objective of this paper is to assess the role of plasmapheresisin immune hematology by reviewing published clinical outcome dataand narrative review articles. This information will be used todefine evidence levels for appraisal of the efficacy and rank ofplasmapheresis among other management options. This evidence\u2010basedstrategy conforms to the concepts of the American Society of Hematology(ASH), as put forward in 1996 in the context of immune thrombocytopenia(ITP) treatment. The term \u2018experimental\u2019 is usedto describe indications where the only scientific evidence of theefficacy of plasmapheresis consists of pathophysiological reasoningand empiric clinical findings. We reviewed the availableliterature on the use of plasmapheresis in autoimmune hemolyticanemia (AIHA), hemolytic disease of the newborn (HDN), autoimmunethrombocytopenic purpura (AITP), heparin\u2010induced thrombocytopeniatype II (HIT II), post\u2010transfusion purpura (PTP), refractorinessto platelet transfusion (RPT), coagulation factor inhibitor (CFI)and catastrophic antiphospholipid syndrome (CAS). Plasmapheresiscompletes the spectrum of management options as it eliminates physicallycirculating free antibodies involved in the pathogenesis of theseimmune hematological syndromes. Because of the paucity of data,evidence levels had to be defined based on the findings of uncontrolledcase series and the opinions of independent experts. In many cases, randomizedclinical trials were not feasible because the syndromes are so rare.When defined as an \u2018experimental indication\u2019,plasmapheresis has a firm scientific basis, but larger scale clinicalexperience with the method is still lacking. In these cases, thedetection and monitoring of symptomatic disease\u2010related circulatingfree antibodies or immune complexes is a mandatory prerequisitefor the use of plasmapheresis. The therapeutic benefit of plasmapheresisis substantiated by the level V of evidence of its efficacy in treatmentof HDN, HIV\u2010associated AITP, induction of tolerance in CFI and inCAS. The goal of future studies should be to establish a firmerbase of scientific evidence for indications classified as experimentalby setting up case series large enough for proper assessment ofplasmapheresis alone or combination with other treatment measures. Thisgoal can only be achieved through multiinstitutional cooperation.<\/jats:p>","DOI":"10.1046\/j.1526-0968.2003.00004.x","type":"journal-article","created":{"date-parts":[[2004,12,29]],"date-time":"2004-12-29T16:07:46Z","timestamp":1104336466000},"page":"127-140","source":"Crossref","is-referenced-by-count":49,"title":["Plasmapheresis in Immune Hematology: Review of Clinical OutcomeData with Respect to Evidence\u2010Based Medicine and Clinical Experience"],"prefix":"10.1111","volume":"7","author":[{"given":"Hans","family":"Von Baeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"31","article-title":"Modulationof immunity in patients with autoimmune disease and cancer treatedby extracorporeal immunoadsorption with PROSORBA columns","volume":"26","author":"Snyder AW","year":"1989","journal-title":"Semin Hematol"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","unstructured":"ImbachP D\u2019ApuzzoV HirtAet al.High\u2010dose intravenous gammaglobulin for idiopathic thrombocytopenicpurpura in children.Lancet1981;II:1228\u201330.","DOI":"10.1016\/S0140-6736(81)92400-4"},{"key":"e_1_2_8_4_2","first-page":"1935","article-title":"Effectof intravenous immunoglobulin in immune thrombocytopenia. Competitiveinhibition of reticuloendothelial system function by sequestrationof autologous red blood cells?","volume":"2","author":"Salama A","year":"1983","journal-title":"Lancet"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70310-5"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422507"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathicthrombocytopenic purpura. A practice guideline developed by explicitmethods for the American Society of Hematology","volume":"88","author":"George NJ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<114::AID-JCA2>3.0.CO;2-8"},{"key":"e_1_2_8_10_2","first-page":"42","article-title":"Biomodulationeffects of extracorporeal circulation in plasmapheresis","volume":"26","author":"Nos\u00e9 Y","year":"1989","journal-title":"Semin Hematol"},{"key":"e_1_2_8_11_2","first-page":"73","article-title":"Theoreticalaspects of immune complex removal by plasmapheresis","volume":"2","author":"Clough JD","year":"1981","journal-title":"Plasma Ther Transfus Technol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","unstructured":"B\u00e9lakM WidderRA BrunnerR BorbergH HauptWF.Immunoadsorption with protein A sepharose or silica.Lancet1994:343.","DOI":"10.1016\/S0140-6736(94)91868-6"},{"key":"e_1_2_8_13_2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V79.9.2237.2237","article-title":"Experience with protein A immunoadsorptionin the treatment\u2010resistant adult immune thrombocytopenic purpura","volume":"79","author":"Snyder HW","year":"1992","journal-title":"Blood"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90843-5"},{"key":"e_1_2_8_15_2","first-page":"144","volume-title":"Postgraduate Haematology","author":"Gordon\u2010Smith EC","year":"1999"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111239.x"},{"key":"e_1_2_8_17_2","first-page":"80","article-title":"Autoimmunedisease and chronic lymphocytic leukemia. Autoimmune hemolytic anemia,pure red cell aplasia, and autoimmune thrombocytopenia","volume":"25","author":"Diehl LF","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812103392410"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30490273444.x"},{"key":"e_1_2_8_20_2","first-page":"13","article-title":"Autoimmune hemolytic anemia and\/or thrombocytopeniaassociated with lupus parameters","volume":"29","author":"Miescher PA","year":"1992","journal-title":"Semin Hematol"},{"key":"e_1_2_8_21_2","first-page":"3","article-title":"Autoimmunehemolytic anemia","volume":"29","author":"Engelfriet CP","year":"1992","journal-title":"Semin Hematol"},{"key":"e_1_2_8_22_2","first-page":"166","article-title":"PEX asa necessary prerequisite for the induction of remission by humanimmunoglobulin in autoimmune hemolytic anemia","volume":"91","author":"Huges P","year":"1994","journal-title":"ActaHaematol"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(95)00501-B"},{"key":"e_1_2_8_24_2","first-page":"67","article-title":"An\u00e9mieh\u00e9molytique auto\u2010immune avec \u00e9rthythroaplasiem\u00e9dullaire et s\u00e9rum noir sur meth\u00e9malbumin\u00e9mie","volume":"123","author":"Betticher DC","year":"1993","journal-title":"Schweiz Med Wschr"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920090205"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1980.20581034517.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422204"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204671"},{"key":"e_1_2_8_29_2","first-page":"1093","article-title":"Autoimmune hemolytic anemia followingT cell\u2010depleted allogeneic bone marrow transplantation","volume":"17","author":"Drobyski WR","year":"1996","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.36.487"},{"key":"e_1_2_8_31_2","first-page":"243","article-title":"Sakurai.Recurrent cold hemagglutinin disease following allogeneic bone marrowtransplantation successfully treated with plasmapheresis, corticosteroidsand cyclophosphamide","volume":"18","author":"Azuma E","year":"1996","journal-title":"Bone Marrow Transpl"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199709000-00005"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1047600"},{"key":"e_1_2_8_34_2","first-page":"454","article-title":"Severe autoimmune hemolytic anemia with marked elevationof monothermic cold agglutinins: Successful treatment by plasmapheresis","volume":"138","author":"Gordjani N","year":"1990","journal-title":"Monatschr Kinderheilkd"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939209150322"},{"key":"e_1_2_8_36_2","first-page":"315","article-title":"Anti\u2010Sacold agglutinin of IgA class requiring plasma exchange therapy asearly manifestation of multiple myeloma","volume":"66","author":"Pereira A","year":"1993","journal-title":"AnnHematol"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1994.34594249056.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880140407"},{"key":"e_1_2_8_39_2","first-page":"164","volume-title":"Postgraduate Haematology","author":"Contreras M","year":"1997"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349509021175"},{"key":"e_1_2_8_41_2","first-page":"783","volume-title":"Fetal Hemolytic Disease in High\u2010Risk Pregnancy ManagementOptions.","author":"Weiner CP","year":"1994"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1991.31491213309.x"},{"key":"e_1_2_8_43_2","first-page":"57S","article-title":"Plasmapheresisin the treatment of repeated early pregnancy wastage associatedwith anti\u2010Pi","volume":"66","author":"Rock JA","year":"1985","journal-title":"Obstet Gynecol"},{"key":"e_1_2_8_44_2","first-page":"451","article-title":"ReviewPlasmapheresis during pregnancy","volume":"76","author":"Watson WJ","year":"1990","journal-title":"Obstet Gynecol"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90111-2"},{"key":"e_1_2_8_46_2","first-page":"209","article-title":"Plateletantibodies and diagnosis of immune\u2010mediated thrombocytopenia","volume":"28","author":"Kiefel V","year":"2001","journal-title":"Inf Ther Transf Med"},{"key":"e_1_2_8_47_2","first-page":"2","article-title":"Drug\u2010inducedimmune thrombocytopenia. An overview of pathogenesis","volume":"36","author":"Aster RH","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_8_48_2","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood.V92.7.2280","article-title":"Thenatural history of alloimmunization to the platelet\u2010specific antigen HPA\u20101a(P1A1,ZWa)","volume":"92","author":"Williamson LM","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911113412004"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80054-1"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010501"},{"key":"e_1_2_8_52_2","first-page":"52","article-title":"Clinicalexperience with anti\u2010D in the treatment of idiopathic thrombocytopenicpurpura","volume":"35","author":"Scaradavou A","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199110000-00017"},{"key":"e_1_2_8_54_2","first-page":"10","article-title":"The effect of immunoadsorption therapyby a protein A column in patients with thrombocytopenia","volume":"26","author":"Muroi K","year":"1989","journal-title":"Semin Hematol"},{"key":"e_1_2_8_55_2","first-page":"3","article-title":"Immunethrombocytopenia purpura: a pilot study of staphylococcal proteinA immunomodulation in refractory patients","volume":"26","author":"Guthrie TH","year":"1989","journal-title":"SeminHematol"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00568.x"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.4065\/71.6.597"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28188127949.x"},{"key":"e_1_2_8_59_2","first-page":"15","article-title":"Treatmentof patients with HIV thrombocytopenia and hemolytic uremic syndromewith protein A (Prosorba column) immunoadsorption","volume":"26","author":"Mittelman A","year":"1989","journal-title":"SeminHematol"},{"key":"e_1_2_8_60_2","first-page":"18","article-title":"Autoimmunethrombocytopenia: Clinical aspects","volume":"29","author":"Waters AH","year":"1992","journal-title":"Semin Hematol"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90114-8"},{"key":"e_1_2_8_62_2","first-page":"38","article-title":"Posttransfusion purpura.The therapeutic value of P1A1\u2010negative platelets","volume":"28","author":"Brecher ME","year":"1988","journal-title":"Transfusion"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33393174450.x"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33393174442.x"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb04943.x"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02876.x"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35895357902.x"},{"key":"e_1_2_8_68_2","first-page":"29","article-title":"Plasmapheresisin the management of heparin\u2010induced thrombocytopenia","volume":"36","author":"Robinson JA","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_8_69_2","first-page":"394","article-title":"Plasmapheresis A therapeutic option in the managementof heparin\u2010associated thrombocytopenia with thrombosis","volume":"96","author":"Brady J","year":"1991","journal-title":"Coagul Transf Med"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830280318"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(98)80386-X"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80049-8"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80050-4"},{"key":"e_1_2_8_74_2","first-page":"280","article-title":"Factor V inhibitor in a liver transplantpatient associated with porcine xenoperfusion","volume":"28","author":"Smith JD","year":"1998","journal-title":"AnnClin Laboratory Sci"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80051-6"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00195.x"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804143181503"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01910319"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00140.x"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1991.31391165179.x"},{"key":"e_1_2_8_81_2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1055\/s-0038-1649876","article-title":"Eliminationof acquired factor VIII antibodies by extracorporeal antibody\u2010basedimmunoadsorption (Ig\u2010Therasorb)","volume":"74","author":"Kn\u00f6bel P","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_82_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000204868","article-title":"Successful treatment of acquiredfactor VIII antibody by extracorporeal immunoadsorption","volume":"85","author":"Negrier C","year":"1991","journal-title":"Acta Haematol"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01220.x"},{"key":"e_1_2_8_84_2","first-page":"639","article-title":"Hemorrhagic disorder due to an isoniazid\u2010associatedacquired factor XIII inhibitor in a patient with Waldenstr\u00f6m\u2019smacroglobulinemia","volume":"90","author":"Krumdieck R","year":"1991","journal-title":"Am J Med"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90028-A"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1987.27387235627.x"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80066-7"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra002974"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199805000-00005"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2003.00004.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:06:27Z","timestamp":1697313987000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-0968.2003.00004.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1046\/j.1526-0968.2003.00004.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-0968.2003.00004.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}